Jun 8, 2026 07:32AM
Jun 8, 2026 07:30AM
Jun 3, 2026 08:00AM
May 28, 2026 08:06AM
May 28, 2026 08:00AM
May 14, 2026 04:30PM
May 6, 2026 07:30AM Medicus Pharma reports positive dose response in skin cancer trial
May 6, 2026 07:30AM
May 1, 2026 02:30PM
Apr 27, 2026 07:39AM
Apr 27, 2026 07:30AM
Apr 27, 2026 07:30AM
Apr 17, 2026 07:31AM
Apr 17, 2026 07:30AM Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome
Apr 15, 2026 07:30AM
Apr 6, 2026 07:31AM
Apr 6, 2026 07:30AM
Apr 1, 2026 07:30AM
Apr 1, 2026 07:30AM
Mar 30, 2026 07:30AM
Mar 30, 2026 07:30AM Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate
Mar 26, 2026 07:30AM
Mar 26, 2026 07:30AM
Mar 25, 2026 04:30PM
Mar 18, 2026 07:30AM
Mar 18, 2026 07:30AM
Mar 16, 2026 07:30AM
Mar 16, 2026 07:30AM Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webca
Mar 10, 2026 07:30AM
Mar 9, 2026 07:30AM
Mar 9, 2026 07:30AM
Mar 5, 2026 07:30AM
Mar 5, 2026 07:30AM
Mar 3, 2026 07:30AM
Feb 12, 2026 07:30AM Medicus Pharma on Bloomberg World
Feb 10, 2026 07:31AM
Feb 10, 2026 07:30AM
Jan 23, 2026 07:30AM
Jan 22, 2026 07:30AM
Jan 22, 2026 07:30AM
Jan 20, 2026 07:30AM
Jan 12, 2026 07:31AM Medicus Pharma study shows stable bone turnover with hormone suppression
Jan 12, 2026 07:30AM
Jan 5, 2026 07:30AM
Jan 5, 2026 07:30AM
Dec 22, 2025 07:31AM
Dec 22, 2025 07:30AM
Dec 15, 2025 07:30AM
Dec 15, 2025 07:30AM Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
Dec 5, 2025 03:26PM

322,971 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All